ストックスクリーナーアプリを入手
7.3521
0.57%
0.0421
Grifols Sa Adr (GRFS) 最新ニュース
Grifols stock trades below recent highs as valuation focus grows - ad-hoc-news.de
Intravenous Immunoglobulin Market Size Worth USD 30.83 Billion by 2035, Growing at 7.49% CAGR – SNS Insider - GlobeNewswire Inc.
Grifols stock edges lower as investors weigh recent earnings and valuation - ad-hoc-news.de
Operating margin % of Grifols, S.A. Sponsored ADR Class A – HAM:G0F - TradingView
Return on invested capital % of Grifols, S.A. Sponsored ADR Class A – HAM:G0F - TradingView
Return on equity % of Grifols, S.A. Sponsored ADR Class A – HAM:G0F - TradingView
Price to earnings ratio of Grifols, S.A. Sponsored ADR Class A – HAM:G0F - TradingView
G0F Forecast — Price Target — Prediction for 2027 - TradingView
G0F Stock Price and Chart — HAM:G0F - TradingView
Grifols stock holds below $8 as half-year 2026 earnings highlight margin progress - ad-hoc-news.de
Grifols stock holds in single digits as Q2 2026 earnings miss consensus by a small margin - Ad-hoc-news.de
ETFs Investing in Grifols, S.A. Sponsored ADR Class B Stocks - TradingView
Grifols Up Over 6%, on Pace for Largest Percent Increase Since May 2025 -- Data Talk - Moomoo
Grifols stock trades below $8 as investors weigh earnings outlook - Ad-hoc-news.de
Grifols, S.A. (GRFS) stock price, news, quote and history - Yahoo Finance UK
Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency - barchart.com
Grifols ADRs Drop 4% to $7.87 as GRFS Nears Key Support at $7.48Insider Buying Alerts - vinanet.vn
Grifols shares jump after Q2 results exceed expectations - Investing.com
Grifols, S.A. Sponsored ADR Class A Revenue Breakdown – MUN:G0F - TradingView
Grifols (GRFS) Q2 2026 Earnings Call Transcript - The Globe and Mail
Grifols SA (GRFS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Grifols, S.A. (GRFS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Grifols doses first patients in two phase 3 immunoglobulin trials By Investing.com - Investing.com UK
G0FB Forecast — Price Target — Prediction for 2027 - TradingView
GRFSGrifols SA ADR Options - Finviz
Grifols operations profile, Sunday focus on plasma and strategy - ad-hoc-news.de
A1C3HH Forecast — Price Target — Prediction for 2027 - TradingView
Grifols, S.A. Class A Actuals & Estimates (BME:GRF) - TradingView
A1J1E2 Forecast — Price Target — Prediction for 2027 - TradingView
Grifols, S.A. Sponsored ADR Class B Actuals & Estimates (NASDAQ:GRFS) - TradingView
Grifols holds technical support, shares trade in a tight Nasdaq range - AD HOC NEWS
Grifols S.A. Stock (ES0171996087): IBEX 35 plasma specialist in focus after modest gain - Ad-hoc-news.de
GRIFOLS SA-ADR (GRFS) Stock Chart - ChartMill
Grifols Shares Edge Lower as Stock Tests Key Support ZoneVolatility Smirk - newsline.com
Grifols ADR (GRFS) Gains 1.47% as Shares Hold Above Key Support LevelSector Leader Stocks - newsline.com
Grifols S.A. stock (ES0171996087): Q1 2026 figures and rising short interest keep focus on Spanish p - AD HOC NEWS
Grifols S.A. stock (ES0171996087): Spain plasma specialist in focus after volatile trading week - AD HOC NEWS
GRFS Stock Price, Quote & Chart | GRIFOLS SA-ADR (NASDAQ:GRFS) - ChartMill
Grifols S.A. stock (ES0171996087): Debt reduction deal, Q1 update and what matters for US investors - AD HOC NEWS
Grifols S.A. stock (ES0171996087): plasma specialist regains momentum after earnings update - AD HOC NEWS
Grifols S.A. stock (ES0171996087): plasma specialist back in focus after debt and governance reset - AD HOC NEWS
Grifols SA stock (ES0171996087): AGM plans and Moody’s outlook shift put debt and governance back - AD HOC NEWS
Grifols SA stock (ES0171996087): shareholders eye 2026 AGM after Moody’s outlook boost - AD HOC NEWS
Brandes reports 24.31% stake in Grifols (NASDAQ: GRFS) in Schedule 13G/A - Stock Titan
0.23%
0.54%
大文字化:
|
ボリューム (24 時間):